Evidence map›Paper›PMID 29389912›Full record

ArticleViruses2018

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.

Birkneh Tilahun Tadesse, Natalie N Kinloch, Bemuluyigza Baraki, Hope R Lapointe, Kyle D Cobarrubias, Mark A Brockman, Chanson J Brumme, Byron A Foster, Degu Jerene, Eyasu Makonnen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Full-spectrum HIV drug resistance mutation detection by high-resolution complete pol gene sequencing.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Birkneh Tilahun TadesseDepartment of Pediatrics, Hawassa University, Hawassa 1506, Ethiopia. birknehtilahun@gmail.com.ORCID 0000-0003-4005-8605
Natalie N KinlochFaculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada. nkinloch@sfu.ca.
Bemuluyigza BarakiFaculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada. bbaraki@sfu.ca.ORCID 0000-0002-4631-3905
Hope R LapointeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada. hlapointe@cfenet.ubc.ca.
Kyle D CobarrubiasFaculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada. kcobarru@sfu.ca.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada. mark_brockman@sfu.ca.ORCID 0000-0001-6432-1426
Chanson J BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada. cbrumme@cfenet.ubc.ca.ORCID 0000-0003-2722-5288
Byron A FosterDepartments of Dermatology and Pediatrics, Oregon Health Sciences University, Portland, OR 97239, USA. bafoster2@hotmail.com.
Degu JereneManagement Sciences for Health, Addis Ababa 1250, Ethiopia. degujerene@gmail.com.
Eyasu MakonnenDepartment of Pharmacology, College of Health Sciences, Addis Ababa University, Addis Ababa 9086, Ethiopia. eyasumakonnen@yahoo.com.
Eleni AklilluDivision of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge C1:68, Stockholm 141 86, Sweden. eleni.aklillu@ki.se.ORCID 0000-0002-9788-0790
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada. zbrumme@sfu.ca.
Simon Fraser University · CAAIDS Vancouver · CAAddis Ababa University · ETHawassa University · ETKarolinska University Hospital · SEOregon Health & Science University · US

Funding

CIHR MFE-146750CIHR PJT-148621
6 · The paper itself

Abstract

Clinical monitoring of pediatric HIV treatment remains a major challenge in settings where drug resistance genotyping is not routinely available. As a result, our understanding of drug resistance, and its impact on subsequent therapeutic regimens available in these settings, remains limited. We investigate the prevalence and correlates of HIV-1 drug resistance among 94 participants of the Ethiopia Pediatric HIV Cohort failing first-line combination antiretroviral therapy (cART) using dried blood spot-based genotyping. Overall, 81% (73/90) of successfully genotyped participants harbored resistance mutations, including 69% (62/90) who harbored resistance to both Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs). Strikingly, 42% of resistant participants harbored resistance to all four NRTIs recommended for second-line use in this setting, meaning that there are effectively no remaining cART options for these children. Longer cART duration and prior regimen changes were significantly associated with detection of drug resistance mutations. Replicate genotyping increased the breadth of drug resistance detected in 34% of cases, and thus is recommended for consideration when typing from blood spots. Implementation of timely drug resistance testing and access to newer antiretrovirals and drug classes are urgently needed to guide clinical decision-making and improve outcomes for HIV-infected children on first-line cART in Ethiopia.

Indexed as

Drug Resistance, ViralAdolescentAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountChildEthiopiaFemaleGenotypeHIV-1HIV InfectionsHumansMalePrevalenceRNA, ViralTreatment FailureAnti-HIV AgentsRNA, Viralchildrendried blood spotsdrug resistanceEthiopiafirst-line combination antiretroviral therapy (cART)genotypingHIVpediatricstreatment failure

Identifiers

PMID29389912
PMCPMC5850367
OpenAlexW2790757720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.